Aging isn’t just bad luck. It’s a cleanup failure.
New research from Stanford Medicine suggests that the accumulation of inflammatory debris is a primary driver of systemic decline. When specialized immune cells lose the ability to sweep away worn-out bodies, the waste sticks. It damages organs. It creates noise.
The culprit? A single inflammatory receptor called EP2.
In experiments with mice, blocking this receptor preserved youthful function across a massive range of tissues. Brain. Heart. Liver. Kidneys. Colon. Spleen. Bone marrow. Skeletal muscle. Mice without the EP2 receptor showed less frailty. They accumulated less fat. They kept their muscle mass. They remembered better. They moved stronger.
“We’ve been trying to figure out why us age,” said Katrin Andreasson. “Now we know at least on big reason for it.”
The findings, published in Science, point to a common source for age-related decline: immune cells that simply can’t keep up with the daily volume of cellular trash.
How Neutrophil Waste Drives Systemic Aging
Think of neutrophils as the immune system’s suicide bombers. They are the most abundant white blood cells, built for speed and destruction. They rush to infections, attacking bacteria and viruses by releasing toxic chemicals. Many even rupture themselves, casting out molecular webs to trap pathogens.
This strategy is effective. It’s also short-lived.
Neutrophils survive for about 12 hours. Roughly 100 billion of them die every 24 hours.
Normally, a cleanup crew handles this volume. The liver, spleen, and bone marrow clear these cells before they cause trouble. But as animals age, that system breaks down.
Neutrophils linger. They enter a damaged state called senescence. Instead of dying quietly, they stay biologically active. They release inflammatory substances. They injure nearby tissue. They encourage other cells to age.
“Senescent neutrophils are Killing our tissues,” Andreasson noted.
The older we get, the higher the percentage of senescent neutrophils in circulation. This persistent inflammation fuels further decline. It’s a feedback loop.
Macrophages Are the Body’s Waste Management Crew
Who handles the disposal? Macrophages.
These are long-lived immune cells living inside organs. They attack pathogens. They support tissue repair. And crucially, they swallow cellular debris. Andreasson calls them the “garbage collection crew.”
Specifically, tissue-resident macrophages are vital. Many enter organs during fetal development. They stay for life. They adapt to the local tissue. Macrophages in the brain do different tasks than those in the liver, but all help maintain the environment.
One of those tasks: removing aging neutrophils.
Neutrophils show signs of age within 8 to 12 hours. They put out “kill me now” signals on their surface. Macrophages should eat them.
But macrophages age, too.
A 2021 Nature study by Andreasson’s team showed these cells gradually lose metabolic energy. They become more sensitive to inflammation. Their performance declines. Damaged cells persist. More inflammation follows.
EP2 Signaling Triggers Immune Breakdown
The new study identifies the switch.
Immune cells produce prostaglandins. PGE2 is one of them. It can help or harm tissue depending on the receptor it hits. The receptor in question here is EP2.
Tissue-resident macrophages have lots of EP2. And EP2 promotes inflammation.
PGE2 levels rise with infection, injury, and age. At the same time, macrophages develop more EP2 receptors. They become hypersensitive.
This creates a double hit.
More PGE2. More EP2 receptors. Stronger inflammatory stimulation. The new research shows this weakens macrophage metabolism. It reduces their ability to engulf aging neutrophins.
Senescent neutrophins accumulate. They release damaging chemicals. Inflammation spikes. The cycle reinforces itself.
“We’ve shown that when tissue-resident Macrophages don’t have EP2… or when that receptor is plugged by a drug, this decline doesn’t,” Andreasson explained.
Blocking EP2 Restores Youthful Function
To test this, the team engineered mice. They could delete the EP2 gene in tissue-resident macrophages at specific times.
They removed the receptor in mice at 4 to 6 months (their “teen” years). They then compared these mice to young controls (6-8 months) and old controls (23-25 months).
The results were stark.
In older normal mice, 71 blood proteins changed significantly. In the EP2-deficient mice, 59 of those remained at youthful levels.
Many of these proteins came from the liver. The liver is enriched in tissue-resident macrophages and dictates much of the body’s metabolic rate.
In normal older mice, senescent Neutrophils piled up in the liver, spleen, and marrow. In the EP2-blocked mice, levels stayed low.
Externally, the difference was clear.
Older mice without EP2 were leaner. More muscular. More capable. They carried less visceral fat. They performed like young mice on tests of organ function, balance, and strength.
Inflammation dropped in the blood, liver, colon heart, kidneys, and the hippocampus—the memory center.
They moved faster. They balanced better. Their forelimb grip strength held up.
Memory benefits followed.
Older animals lacking EP2 navigatedmazes and recognized objects almost as well as the young mice. Their memory substantially outperformed that of aged mice with intact EP2 receptors.
The data suggests a broader truth. Restoring immune cleanup protects organs. Not by treating specific diseases. But by removing a shared source of chronic damage.
Why Current Anti-Inflammatories Miss the Mark
No approved drug currently blocks EP2 specifically.
Broad painkillers like aspirin reduce PGE2 production. They tackle pain, fever, swelling, and redness. But PGE2 isn’t always bad. It activates various receptors. Some pathways are essential for health.
Broadly blocking prostaglandins interferes with beneficial processes. It’s a sledgehammer when we need a scalpel.
A drug aimed only at EP2 could be more precise. It would weaken the inflammatory signal without breaking the useful functions.
In a lab test, researchers gave 22-month-old mice an experimental EP2 inhibitor for two months. The treatment lowered both total and senescent Neutrophil numbers. Back to youthful ranges.
In petri dishes, macrophages from old mice were terrible at eating worn-out neutrophils. The drug restored that ability.
Human cells showed the exact same pattern.
Human Liver Data Confirms the Mouse Model
The team checked a massive database of human liver cells. Young, old, and diseased livers were analyzed.
Older livers had more Neutrophils. More signs of senescence. Weaker macrophage activity. Stronger EP2 signaling.
The changes were even more pronounced in diseased human livers.
“This was the first time the full pattern has been identified in human cells,” Andreasson said.
The Path Forward
The study does not prove that blocking EP2 slows aging in humans. It’s a mouse model. And a drug safe for long-term use hasn’t been built yet.
But the similarities are too strong to ignore.
The goal isn’t to suppress inflammation everywhere. That’s too broad. The goal is narrower. Restore the immune system’s ability to remove the very cells that produce the inflammation.
“We need to develop a safe drug that disables EP2 without interfering earlier processes like PGE2 production,” Andreasson concluded.
It’s a single switch. One receptor. And it might be the difference between a healthy old age and a system that collapses under its own waste.
The science is there. Now comes the chemistry. And the safety trials. And the years.
But for the first time, the mechanism is clear.
